Exploring the Case for Eminent Domain of Hepatitis C Virus Treatment Patents

Hepatitis C virus (HCV) is a silent epidemic affecting millions of patients and represents the leading indication for liver transplantation in the United States and worldwide. New direct-acting antiviral agents offer the potential to cure patients infected with HCV but it comes at a staggering cost....

Full description

Saved in:
Bibliographic Details
Published in:Journal of health care for the poor and underserved 2017-05, Vol.28 (2), p.621-625
Main Authors: Mattingly II, T. Joseph, Heil, Emily L, Hoke, Kathleen S
Format: Article
Language:English
Subjects:
Antiviral agents
Antiviral Agents - economics
Antiviral Agents - therapeutic use
Antiviral drugs
Benzimidazoles - economics
Benzimidazoles - therapeutic use
Budgets
Cost analysis
Cure
Drug Combinations
Drug Costs
Drug Industry - legislation & jurisprudence
Eminent domain
Epidemics
Expenditures
Fair market value
Federal government
Fluorenes - economics
Fluorenes - therapeutic use
Health care access
Hepatitis
Hepatitis C
Hepatitis C - drug therapy
Hepatology
Humans
Imprisonment
Infections
Jurisprudence
Liver
Liver transplantation
Manufacturers
Medicare
Patents as Topic
Patients
Pharmaceuticals
Prescription drugs
Property rights
Public Health
Staggering
Transplantation
Transplants
Uninsured people
United States
Uridine Monophosphate - analogs & derivatives
Uridine Monophosphate - economics
Uridine Monophosphate - therapeutic use
Viruses
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c366t-25a2d9ff5b06c1807b3da2c9ee5b48c0a00e8e44677dc31ca2ada49eba34679e3
cites
container_end_page 625
container_issue 2
container_start_page 621
container_title Journal of health care for the poor and underserved
container_volume 28
creator Mattingly II, T. Joseph
Heil, Emily L
Hoke, Kathleen S
description Hepatitis C virus (HCV) is a silent epidemic affecting millions of patients and represents the leading indication for liver transplantation in the United States and worldwide. New direct-acting antiviral agents offer the potential to cure patients infected with HCV but it comes at a staggering cost. Given the recent attention to these high-priced HCV therapies and the impact treating individuals with HCV is having on drug expenditures in the United States, there may be a need to revisit drug patent laws and the options the federal government has to ensure patient access to care.
doi_str_mv 10.1353/hpu.2017.0062
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1901309569</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1901309569</sourcerecordid><originalsourceid>FETCH-LOGICAL-c366t-25a2d9ff5b06c1807b3da2c9ee5b48c0a00e8e44677dc31ca2ada49eba34679e3</originalsourceid><addsrcrecordid>eNpdkctr3DAQh0VJyPvYaxHk0ou3I8mSpWPZbJPCQgN5XIUsjxsv60clGZr_vjJ5QU8zDB-_Gb4h5DODFRNSfHua5hUHVq0AFP9ETpgsdaG0Mge5h9IUHLQ5Jqcx7gBAiFIckWOuJTec8ROy3fyd9mPoht80PSFdu4i0HQPd9N2AQ6JXY--6gY4tvcHJpS51ka7pYxfmSO8DutQv1K1LucRzcti6fcSL13pGHn5s7tc3xfbX9c_1923hhVKp4NLxxrStrEF5pqGqReO4N4iyLrUHB4Aay1JVVeMF8467xpUGayfyzKA4I19fcqcw_pkxJtt30eN-7wYc52iZASbASGUyevkfuhvnMOTrLGeKQaWk4JkqXigfxhgDtnYKXe_Cs2VgF802a7aLZrtozvyX19S57rF5p9-8ZqB8X7tDn_o54sdmJbVR2t4tv1pexSoOOVuKfyE_h4k</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2161076532</pqid></control><display><type>article</type><title>Exploring the Case for Eminent Domain of Hepatitis C Virus Treatment Patents</title><source>Applied Social Sciences Index &amp; Abstracts (ASSIA)</source><source>Project Muse:Jisc Collections:Project MUSE Journals Agreement 2024:Premium Collection</source><source>Social Science Premium Collection</source><source>Sociology Collection</source><creator>Mattingly II, T. Joseph ; Heil, Emily L ; Hoke, Kathleen S</creator><creatorcontrib>Mattingly II, T. Joseph ; Heil, Emily L ; Hoke, Kathleen S</creatorcontrib><description>Hepatitis C virus (HCV) is a silent epidemic affecting millions of patients and represents the leading indication for liver transplantation in the United States and worldwide. New direct-acting antiviral agents offer the potential to cure patients infected with HCV but it comes at a staggering cost. Given the recent attention to these high-priced HCV therapies and the impact treating individuals with HCV is having on drug expenditures in the United States, there may be a need to revisit drug patent laws and the options the federal government has to ensure patient access to care.</description><identifier>ISSN: 1049-2089</identifier><identifier>ISSN: 1548-6869</identifier><identifier>EISSN: 1548-6869</identifier><identifier>DOI: 10.1353/hpu.2017.0062</identifier><identifier>PMID: 28529212</identifier><language>eng</language><publisher>United States: Johns Hopkins University Press</publisher><subject>Antiviral agents ; Antiviral Agents - economics ; Antiviral Agents - therapeutic use ; Antiviral drugs ; Benzimidazoles - economics ; Benzimidazoles - therapeutic use ; Budgets ; Cost analysis ; Cure ; Drug Combinations ; Drug Costs ; Drug Industry - legislation &amp; jurisprudence ; Eminent domain ; Epidemics ; Expenditures ; Fair market value ; Federal government ; Fluorenes - economics ; Fluorenes - therapeutic use ; Health care access ; Hepatitis ; Hepatitis C ; Hepatitis C - drug therapy ; Hepatology ; Humans ; Imprisonment ; Infections ; Jurisprudence ; Liver ; Liver transplantation ; Manufacturers ; Medicare ; Patents as Topic ; Patients ; Pharmaceuticals ; Prescription drugs ; Property rights ; Public Health ; Staggering ; Transplantation ; Transplants ; Uninsured people ; United States ; Uridine Monophosphate - analogs &amp; derivatives ; Uridine Monophosphate - economics ; Uridine Monophosphate - therapeutic use ; Viruses</subject><ispartof>Journal of health care for the poor and underserved, 2017-05, Vol.28 (2), p.621-625</ispartof><rights>Copyright © Meharry Medical College.</rights><rights>Copyright Johns Hopkins University Press May 2017</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c366t-25a2d9ff5b06c1807b3da2c9ee5b48c0a00e8e44677dc31ca2ada49eba34679e3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2161076532?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,12846,21394,21395,27924,27925,30999,33611,33612,34530,34531,43733,44115</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28529212$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mattingly II, T. Joseph</creatorcontrib><creatorcontrib>Heil, Emily L</creatorcontrib><creatorcontrib>Hoke, Kathleen S</creatorcontrib><title>Exploring the Case for Eminent Domain of Hepatitis C Virus Treatment Patents</title><title>Journal of health care for the poor and underserved</title><addtitle>J Health Care Poor Underserved</addtitle><description>Hepatitis C virus (HCV) is a silent epidemic affecting millions of patients and represents the leading indication for liver transplantation in the United States and worldwide. New direct-acting antiviral agents offer the potential to cure patients infected with HCV but it comes at a staggering cost. Given the recent attention to these high-priced HCV therapies and the impact treating individuals with HCV is having on drug expenditures in the United States, there may be a need to revisit drug patent laws and the options the federal government has to ensure patient access to care.</description><subject>Antiviral agents</subject><subject>Antiviral Agents - economics</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Antiviral drugs</subject><subject>Benzimidazoles - economics</subject><subject>Benzimidazoles - therapeutic use</subject><subject>Budgets</subject><subject>Cost analysis</subject><subject>Cure</subject><subject>Drug Combinations</subject><subject>Drug Costs</subject><subject>Drug Industry - legislation &amp; jurisprudence</subject><subject>Eminent domain</subject><subject>Epidemics</subject><subject>Expenditures</subject><subject>Fair market value</subject><subject>Federal government</subject><subject>Fluorenes - economics</subject><subject>Fluorenes - therapeutic use</subject><subject>Health care access</subject><subject>Hepatitis</subject><subject>Hepatitis C</subject><subject>Hepatitis C - drug therapy</subject><subject>Hepatology</subject><subject>Humans</subject><subject>Imprisonment</subject><subject>Infections</subject><subject>Jurisprudence</subject><subject>Liver</subject><subject>Liver transplantation</subject><subject>Manufacturers</subject><subject>Medicare</subject><subject>Patents as Topic</subject><subject>Patients</subject><subject>Pharmaceuticals</subject><subject>Prescription drugs</subject><subject>Property rights</subject><subject>Public Health</subject><subject>Staggering</subject><subject>Transplantation</subject><subject>Transplants</subject><subject>Uninsured people</subject><subject>United States</subject><subject>Uridine Monophosphate - analogs &amp; derivatives</subject><subject>Uridine Monophosphate - economics</subject><subject>Uridine Monophosphate - therapeutic use</subject><subject>Viruses</subject><issn>1049-2089</issn><issn>1548-6869</issn><issn>1548-6869</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>7QJ</sourceid><sourceid>ALSLI</sourceid><sourceid>HEHIP</sourceid><sourceid>M2S</sourceid><recordid>eNpdkctr3DAQh0VJyPvYaxHk0ou3I8mSpWPZbJPCQgN5XIUsjxsv60clGZr_vjJ5QU8zDB-_Gb4h5DODFRNSfHua5hUHVq0AFP9ETpgsdaG0Mge5h9IUHLQ5Jqcx7gBAiFIckWOuJTec8ROy3fyd9mPoht80PSFdu4i0HQPd9N2AQ6JXY--6gY4tvcHJpS51ka7pYxfmSO8DutQv1K1LucRzcti6fcSL13pGHn5s7tc3xfbX9c_1923hhVKp4NLxxrStrEF5pqGqReO4N4iyLrUHB4Aay1JVVeMF8467xpUGayfyzKA4I19fcqcw_pkxJtt30eN-7wYc52iZASbASGUyevkfuhvnMOTrLGeKQaWk4JkqXigfxhgDtnYKXe_Cs2VgF802a7aLZrtozvyX19S57rF5p9-8ZqB8X7tDn_o54sdmJbVR2t4tv1pexSoOOVuKfyE_h4k</recordid><startdate>20170501</startdate><enddate>20170501</enddate><creator>Mattingly II, T. Joseph</creator><creator>Heil, Emily L</creator><creator>Hoke, Kathleen S</creator><general>Johns Hopkins University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0-V</scope><scope>3V.</scope><scope>7QJ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8C1</scope><scope>8FI</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ALSLI</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BSCPQ</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>HEHIP</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2S</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PATMY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>PYCSY</scope><scope>Q9U</scope><scope>UXAQP</scope><scope>7X8</scope></search><sort><creationdate>20170501</creationdate><title>Exploring the Case for Eminent Domain of Hepatitis C Virus Treatment Patents</title><author>Mattingly II, T. Joseph ; Heil, Emily L ; Hoke, Kathleen S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c366t-25a2d9ff5b06c1807b3da2c9ee5b48c0a00e8e44677dc31ca2ada49eba34679e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Antiviral agents</topic><topic>Antiviral Agents - economics</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Antiviral drugs</topic><topic>Benzimidazoles - economics</topic><topic>Benzimidazoles - therapeutic use</topic><topic>Budgets</topic><topic>Cost analysis</topic><topic>Cure</topic><topic>Drug Combinations</topic><topic>Drug Costs</topic><topic>Drug Industry - legislation &amp; jurisprudence</topic><topic>Eminent domain</topic><topic>Epidemics</topic><topic>Expenditures</topic><topic>Fair market value</topic><topic>Federal government</topic><topic>Fluorenes - economics</topic><topic>Fluorenes - therapeutic use</topic><topic>Health care access</topic><topic>Hepatitis</topic><topic>Hepatitis C</topic><topic>Hepatitis C - drug therapy</topic><topic>Hepatology</topic><topic>Humans</topic><topic>Imprisonment</topic><topic>Infections</topic><topic>Jurisprudence</topic><topic>Liver</topic><topic>Liver transplantation</topic><topic>Manufacturers</topic><topic>Medicare</topic><topic>Patents as Topic</topic><topic>Patients</topic><topic>Pharmaceuticals</topic><topic>Prescription drugs</topic><topic>Property rights</topic><topic>Public Health</topic><topic>Staggering</topic><topic>Transplantation</topic><topic>Transplants</topic><topic>Uninsured people</topic><topic>United States</topic><topic>Uridine Monophosphate - analogs &amp; derivatives</topic><topic>Uridine Monophosphate - economics</topic><topic>Uridine Monophosphate - therapeutic use</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mattingly II, T. Joseph</creatorcontrib><creatorcontrib>Heil, Emily L</creatorcontrib><creatorcontrib>Hoke, Kathleen S</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Social Sciences Premium Collection【Remote access available】</collection><collection>ProQuest Central (Corporate)</collection><collection>Applied Social Sciences Index &amp; Abstracts (ASSIA)</collection><collection>Nursing &amp; Allied Health Database (ProQuest)</collection><collection>ProQuest Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>Social Science Premium Collection</collection><collection>Agricultural &amp; Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>Black Studies Center</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>Sociology Collection</collection><collection>Family Health Database (Proquest)</collection><collection>Health Management Database (Proquest)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Psychology Database (ProQuest)</collection><collection>ProQuest research library</collection><collection>Sociology Database (ProQuest)</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Environmental Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>Environmental Science Collection</collection><collection>ProQuest Central Basic</collection><collection>ProQuest Black Studies</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of health care for the poor and underserved</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mattingly II, T. Joseph</au><au>Heil, Emily L</au><au>Hoke, Kathleen S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Exploring the Case for Eminent Domain of Hepatitis C Virus Treatment Patents</atitle><jtitle>Journal of health care for the poor and underserved</jtitle><addtitle>J Health Care Poor Underserved</addtitle><date>2017-05-01</date><risdate>2017</risdate><volume>28</volume><issue>2</issue><spage>621</spage><epage>625</epage><pages>621-625</pages><issn>1049-2089</issn><issn>1548-6869</issn><eissn>1548-6869</eissn><abstract>Hepatitis C virus (HCV) is a silent epidemic affecting millions of patients and represents the leading indication for liver transplantation in the United States and worldwide. New direct-acting antiviral agents offer the potential to cure patients infected with HCV but it comes at a staggering cost. Given the recent attention to these high-priced HCV therapies and the impact treating individuals with HCV is having on drug expenditures in the United States, there may be a need to revisit drug patent laws and the options the federal government has to ensure patient access to care.</abstract><cop>United States</cop><pub>Johns Hopkins University Press</pub><pmid>28529212</pmid><doi>10.1353/hpu.2017.0062</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1049-2089
ispartof Journal of health care for the poor and underserved, 2017-05, Vol.28 (2), p.621-625
issn 1049-2089
1548-6869
1548-6869
language eng
recordid cdi_proquest_miscellaneous_1901309569
source Applied Social Sciences Index & Abstracts (ASSIA); Project Muse:Jisc Collections:Project MUSE Journals Agreement 2024:Premium Collection; Social Science Premium Collection; Sociology Collection
subjects Antiviral agents
Antiviral Agents - economics
Antiviral Agents - therapeutic use
Antiviral drugs
Benzimidazoles - economics
Benzimidazoles - therapeutic use
Budgets
Cost analysis
Cure
Drug Combinations
Drug Costs
Drug Industry - legislation & jurisprudence
Eminent domain
Epidemics
Expenditures
Fair market value
Federal government
Fluorenes - economics
Fluorenes - therapeutic use
Health care access
Hepatitis
Hepatitis C
Hepatitis C - drug therapy
Hepatology
Humans
Imprisonment
Infections
Jurisprudence
Liver
Liver transplantation
Manufacturers
Medicare
Patents as Topic
Patients
Pharmaceuticals
Prescription drugs
Property rights
Public Health
Staggering
Transplantation
Transplants
Uninsured people
United States
Uridine Monophosphate - analogs & derivatives
Uridine Monophosphate - economics
Uridine Monophosphate - therapeutic use
Viruses
title Exploring the Case for Eminent Domain of Hepatitis C Virus Treatment Patents
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T00%3A43%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Exploring%20the%20Case%20for%20Eminent%20Domain%20of%20Hepatitis%20C%20Virus%20Treatment%20Patents&rft.jtitle=Journal%20of%20health%20care%20for%20the%20poor%20and%20underserved&rft.au=Mattingly%20II,%20T.%20Joseph&rft.date=2017-05-01&rft.volume=28&rft.issue=2&rft.spage=621&rft.epage=625&rft.pages=621-625&rft.issn=1049-2089&rft.eissn=1548-6869&rft_id=info:doi/10.1353/hpu.2017.0062&rft_dat=%3Cproquest_cross%3E1901309569%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c366t-25a2d9ff5b06c1807b3da2c9ee5b48c0a00e8e44677dc31ca2ada49eba34679e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2161076532&rft_id=info:pmid/28529212&rfr_iscdi=true